Your browser doesn't support javascript.
loading
Progress of programmed death ligand 2 in immunotherapy of solid tumors / 肿瘤研究与临床
Cancer Research and Clinic ; (6): 641-644, 2021.
Article in Chinese | WPRIM | ID: wpr-912939
ABSTRACT
With the breakthrough of immune checkpoint blocking therapy in the clinical treatment of a variety of malignant solid tumors, tumor immunotherapy has opened a new era. However, clinical practice has proved that the response rate of this therapy is low. Seeking for the key factors limiting its response rate has become a research hotspot in this field. Programmed death ligand 2 (PD-L2) is the second important ligand binding to programmed death 1 (PD-1) after programmed death ligand 1 (PD-L1). The encoded protein can bind to PD-1 and then inhibit immune cells. This paper reviews the biological characteristics of PD-L2, its mechanism in immune regulation and its research progress in solid tumor immunotherapy to provide more theoretical support for solid tumor immunotherapy.

Full text: Available Index: WPRIM (Western Pacific) Language: Chinese Journal: Cancer Research and Clinic Year: 2021 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Language: Chinese Journal: Cancer Research and Clinic Year: 2021 Type: Article